This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reply to Letter to the Editor “Is Divalproex a Cost Effective Alternative in the Acute and Prophylactic Treatment of Bipolar I Disorder?”

Paul E. Keck, Jr., Jerry A. Bennett, and Sean P. Stanton

Published: November 15, 1997

Article Abstract

Letter to the Editor

Sir: We thank Drs. Dardennes and Even for their interest in our article and for their comments. Our conclusions from the decision- analytic model proposed in our article were that, based on the available evidence, divalproex appeared to be less costly overall in the treatment of patients with bipolar disorder, but that cost differences were also dependent on the type of manic syndrome. For patients with classic mania, lithium appeared to be less costly, whereas for mixed mania or rapid cycling, divalproex appeared to have a cost advantage.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: